Dynamic Biomarkers of Response to Antiangiogenic Therapies in Colorectal Cancer: A Review

Jesus Rodriguez-Pascual* and Antonio Cubillo

Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain

Abstract: Background: Identification of clinical and molecular biomarkers to predict dynamic response or monitor in real-time the efficacy of antiangiogenic therapy represents a major point in the treatment of patients with advanced colorectal cancer. Several studies have been conducted to identify some predictive biomarkers to select patients who will benefit from bevacizumab, the most widely used antiangiogenic monoclonal antibody.

Conclusion: After a decade since the introduction of bevacizumab, no effective predictive biomarkers are available in routine clinical practice. In this review, we summarized the potential candidate dynamic biomarkers that may play a role in this setting.

Keywords: Colorectal cancer, bevacizumab, biomarkers, angiogenesis, chemotherapy, metastatic disease.

1. INTRODUCTION

Colorectal cancer is the second most common cancer in women (614,000 cases) and the third most common cancer in men (746,000 cases) worldwide, with 694,000 deaths every year [1]. New biological therapies based on angiogenesis blockade were approved over the last year for the treatment of patients with metastatic disease.

Bevacizumab was the first molecular-targeted antiangiogenic therapy approved by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). An increased expression of Vascular Endothelial Growth Factor A (VEGFA) has been found in most human cancers examined, including colon cancer [2, 3]. This monoclonal antibody binds to the circulating VEGFA which inhibits tumor angiogenesis [4, 5]. In advanced colorectal cancer, bevacizumab has been shown to increase the overall survival (OS), the progression-free survival (PFS) and the response rate (RR) in a first-line treatment associated with 5-fluorouracil/leucovorin/irinotecan (IFL) and in combination with 5-fluorouracil/leucovorin, or capecitabine alone [6]. Bevacizumab has also been shown to improve the PFS in combination with fluoropyrimidines plus oxaliplatin in the first-line treatment [7]. Furthermore, the triplet drug combination FOLFOXIRI plus bevacizumab presents one of the longest survivals reported up to date [8]. Therefore, bevacizumab added to standard chemotherapy is recommended as a first-line treatment for patients with potentially resectable and unresectable metastatic disease [9, 10].

By other part, bevacizumab has been shown to prolong marginally survival among patients with metastatic colorectal cancer at a relatively high cost [11]. In fact, bevacizumab appear to not be a cost-effective treatment and is deemed to be of low value at their current cost. Using biomarkers to treat only the patients likely to get a significant survival benefit would also improve safety, quality of life and cost-effectiveness.

To date, no validated biomarkers have been established for antiangiogenic-based colorectal cancer treatment [12-14]. The aim of this report is to describe the most promising biomarkers to evaluate the antiangiogenic effect of antiangiogenic therapy in this setting.

2. CLINICAL PREDICTORS

2.1. Blood Pressure

Hypertension has been found in patients treated with anti-VEGF therapies. Several randomized trials have shown that bevacizumab improves both progression-free survival (PFS) and overall survival (OS). In all these studies hypertension was observed to be a
common side effect associated with bevacizumab. Hypertension has been suggested to predict treatment efficacy in patients with CRC [15, 16]. Osterlund et al. [17] described a study to evaluate the association between treatment-related hypertension, outcome and safety following treatment with bevacizumab-containing chemotherapy. The study evidenced that early hypertension was predictive for an improved OS. Other studies showed an association between VEGF genotype and the development of clinically significant hypertension. Thus, hypertension is thought to be a possible clinical predictor of response.

3. IMAGING PREDICTORS

3.1. Ultrasound Imaging

A recent study in murine colon cancer models using three-dimensional dynamic contrast-enhanced ultrasound imaging [18] provides information on the variability of tumor response to antiangiogenic therapy and may be further developed as biomarker for predicting treatment outcomes.

3.2. MRI

Response and time progression could be evaluated with surrogate biomarkers in bevacizumab-containing regimen of advanced colorectal cancer patients. Pharmacokinetic parameters obtained via dynamic contrast-enhanced magnetic resonance imaging (MRI) could be a good option to explore [19].

3.3. CT Scan

A clear relationship between response to bevacizumab and the degree of contrast enhancement in evaluation by computed tomography (CT) of colorectal liver metastasis were found. Dynamic changes in the radiological parameters after contrast injection confirmed the potential of these blood perfusion as surrogate predictors [20].

Dighe et al. [21] investigated the ability of perfusion CT to quantify the degree of angiogenesis in colorectal cancer patients. Perfusion parameters calculated were correlated with the measurement of Microvessel Density (MVD) obtained from immunohistochemical staining of resected surgical specimens. Perfusion CT is also able to integrate anatomical detail with the assessment of vascular physiology. Pharmacokinetic modeling after tumor enhancement achieved by contrast administration allows the physiologically based quantitative vascular parameters [22, 23]. Perfusion CT may reflect angiogenesis in colorectal cancer; however, not all studies have been able to correlate blood flow with MVD [24, 25]. Perfusion measurements have also been shown to be robust enough to be useful for therapeutic assessment in colon cancer [26].

3.4. Positron Emission Tomography

Although Fluodeoxyglucose Positron Emission Tomography (FDG PET) is a biomarker of response to targeted therapy, (e.g., imatinib in gastrointestinal stromal tumors), early reductions in standardized uptake value have not been evaluated in patients with colon treated with bevacizumab-based therapy. However, it may provide the detection of early stages of response to EGFR-targeted TKIs in colon cancer [27].

4. MOLECULAR PREDICTORS

4.1. VEGF/PIGF

Circulating VEGF. Correlation between the efficacy of antiangiogenesis treatment and circulating VEGF levels have been explored in several clinical trials. Some phase II studies have shown that the elevated levels of VEGF have been associated with a poor prognosis, instead of being a biomarker of response [28-31]. A phase II study of bevacizumab combined with chemotherapy in rectal cancer showed no correlation between VEGF levels and the outcome of therapy [32]. However, studies in other tumor types [33, 34] showed inconsistent results.

PIGF and soluble VEGF receptors. Circulating levels of PIGF have been shown to increase in response to angi-VEGF therapies. Thus, targeting PIGF is being considered as a new approach to prevent tumor resistance. Increased levels of PIGF in plasma has been associated with an improved outcome in patients with rectal cancer treated with bevacizumab. Thus, circulating levels of soluble VEGFR2 and VEGFR3 have been shown to be decreased by TKIs that directly target these receptors [35-39], however, they are unaffected by bevacizumab [34]. By other part, KDR (kinase insert domain receptor) is the human gene encoding for vascular endothelial growth factor receptor 2 (VEGFR-2), and preliminary data showed that there is a potential relationship between KDR mutation and regorafenib [40]. VEGFR-2 is also a potential biomarker of Aflibercept in the recent studies [41].

5. CIRCULATING ENDOTHELIAL CELLS AND ENDOTHELIAL PROGENITORS

Blood-circulating cells have been studied as potential biomarkers of angiogenic therapy. Willet et al. found that bevacizumab reduced the number of viable circulating endothelial cell progenitors in patients with rectal cancer [42]. However, other studies found no differences in circulating cell levels [43].

Zuurbier et al. in a recent study [44] performed a DNA microarray-based transcriptional profiling screen with primary endothelial cells (ECs) isolated from normal and tumoral colon tissues. Thirteen separate populations of tumour-associated ECs and 10 of nor-
mal ECs were isolated using fluorescence-activated cell sorting. Transcriptional profiling revealed a total of 2,610 differentially expressed genes when tumoral and normal ECs were compared. In patients treated with bevacizumab in the adjuvant setting expression of MMP12 and Apelin (APL) mRNA was significantly higher in bevacizumab non-responders compared to responders. At the protein level, high APLN expression was correlated with poor progression-free survival in bevacizumab-treated patients.

6. ANGIOPGENIC SWITCH

Kopetz et al. [45] evaluated changes in plasma cytokines and some angiogenic factors (CAF) in a first line phase II trial bevacizumab-containing treatment for patients with advanced colorectal cancer. Elevated interleukins (IL)-8 at baseline was associated with shorter PFS (p=0.03) Before the radiographic development of progression, several CAFs increased in comparison to baseline, including basic fibroblast growth factor, hepatocyte growth factor, placental growth factor, stromal-derived factor-1 and macrophage chemoattractant protein-3.

Cubillo et al. [46] tested these results in another prospective phase II in whom patients with mCRC received treatment with XELIRI- or XELOX- bevacizumab. Initial treatment was followed by maintenance therapy (bevacizumab plus capecitabine) until progression. Plasma levels of angiogenic-related cytokines (HGF, PIGF, MCP-3, MM-9, Eotaxin, bFGF and IL-18) were analyzed. Maintenance treatment result in dynamic changes in plasma cytokines associated with better disease control and longer PFS.

High serum levels of Epidermal Growth Factor (EGF) and macrophage-derived chemokine and low levels of IL-10, IL-6 and IL-8 were associated with a higher likelihood of response to treatment [47]. IL-8 has also been reported to mediate angiogenesis by stimulating the endothelial cell proliferation in response to hypoxia [48], and resistance to angiogenic therapy has been associated with an increased secretion of IL-8 [38].

Hayashi et al. [49] evaluated 25 angiogenesis-related molecules for 25 CRC patients both before and during treatment in a previously reported phase II trial of FOLFIRI chemotherapy plus bevacizumab. The serum concentration of VEGFA decreased after the onset of treatment, whereas that of placental growth factor significantly increased. The results suggest that an early increase in the serum VEGFA concentration after the initial decrease is a potential predictive marker of a poor response and reactive resistance to bevacizumab plus chemotherapy.

7. IMMUNOGENICITY

7.1. Microsatellite Instability (MSI)

MMR-deficient colorectal cancer patients show an enhanced immunogenicity and an increased number of intra-epithelial lymphocytes that may be associated with a favorable clinical outcome [50]. High Microsatellite instability (H-MSI) colorectal cancer tumors may follow a different pathway to angiogenesis. VEGF expression has been found lower among H-MSI adenocarcinomas, and this could partially explain why these group of tumors are less aggressive.

7.2. Immunogeniticy/Cadherin

Some studies indicate that there is a significant host response associated with an improved prognosis of patients with advanced colorectal cancer treated in base to antiangiogenic drugs (e.g. aflibercept), suggesting that it may alter the natural history of this disease. The mobilization of immune cells, such as myeloid-derived suppressor cells (MDSCs), has been thought to contribute to drug resistance. Recent studies have shown that VEGFA signaling through VEGFR2 is involved in MDSCs recruitment to metastases, and once within the tumor, these can mature into tumor-promoting macrophages. Other angiogenic factors, such as PIGF, directly or indirectly stimulate angiogenesis by affecting a wide range of different cell types or by attracting MDSCs and macrophages within the tumor microenvironment. PIGF also promotes inflammation and angiogenesis by interacting with an alternative pathway via VEGFR1 signalling [51].

Ma et al. described that CDH12 (Cadherin 12) promotes proliferation, migration and angiogenesis in colorectal cancer, and is expected to become a new diagnostic and prognostic marker, as well as potential new target of treatment for colorectal cancer. The authors concluded that CDH12 might act as a predictor of prognosis in patients with colon cancer [52].

Leucine-rich-alpha-2-glycoprotein 1 (LRG1) has been associated with several tumors and shown to be overexpressed in colon cancer patients, specially in more aggressive tumors. LRG1 induces the process of cell migration and invasion. It also promotes VEGFA expression in colon cancer cells and, therefore, contributes to tumor angiogenesis. HIF1 alpha can also be induced by LRG1 and is thought to be the mechanism by which LRG1 induces VEGFA expression and epithelial-to-mesenchymal transitions (EMT) [53].

CONCLUSION AND FUTURE DIRECTIONS

There is increasing evidence about the potential predictors of bevacizumab efficacy and a biological rationale to support such observations. Nonetheless, due to the lack of a randomized study design, the ab-
sence of prospective validation of data, or the inability to routinely use these markers, the findings were viewed with caution and have not been used in clinical practice. On the other hand, the addition of bevacizumab to cytotoxic chemotherapy as first- or second-line treatment is associated with an improvement in the outcome of all subgroups of mCRC patients. However, it is essential to identify biomarkers that permit the recognition of potentially responsive subjects and to spare those unlikely to benefit unnecessary toxicity.

In spite of the high number of static biomarker in the literature, the role of dynamic biomarker evaluating the angiogenic switch effect and the combination of clinical and radiological data in real time may result in future and successful research approaches.

CONSENT FOR PUBLICATION

Not applicable.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS

Declared none.

REFERENCES

[1] International Agency for Research on Cancer. GLOBOCAN. Estimated Cancer Incidence Worldwide in 2012. [Available at: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. (Accessed: June 11, 2015).

[2] Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4-25.

[3] Lee JC, Chow NH, Wang ST, et al. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 2000; 36: 748-53.

[4] Giontonio BJ, Levy DE, O’dywer PJ, et al. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: Results from the Eastern cooperative oncology group study E2200. Ann Oncol 2006; 17: 1399-403.

[5] Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999; 77: 527-43.

[6] Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.

[7] Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in colorectal cancer with liver metastasis. Int J Cancer 2012; 130: 599-604.

[8] Zhou J, Zhang H, Wang H, et al. Early prediction of tumor response to bevacizumab treatment in murine colon cancer models using three-dimensional dynamic contrast-enhanced ultrasound imaging. Angiogenesis doi: 10.1007/s10456-017-9566-5.

[9] Hirashima Y, Yamada Y, Tateishi U, et al. Pharmacokinetic parameters from 3-tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis. Int J Cancer 2012; 130: 2359-65.

[10] Lee L, Sharma S, Morgan B, et al. Biomarkers for assessment of pharmaco-logic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases. Cancer Chemother Pharmacol 2006; 57(6): 761-71.

[11] Troprès I, Lamalle L, Péoc’h M, et al. Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging. J Magn Reson Imaging 2009; 29: 1125-33.

[12] Walker-Samuel S, Boulh JK, et al. Non-invasive in vivo imaging of vessel calibre in orthotopic prostate tumour xenografts. Int J Cancer 2012; 130: 1284-93.

[13] Van Cutsem E, Cervantes A, Nordlinger B, et al. On behalf of the ESMO Guidelines. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25(Suppl 3): iii1-9.

[14] Goldstein DA, Zeichner SB, Bartnik CM, et al. Metastatic colorectal cancer: A systematic review of the value of current therapies. Clin Colorectal Cancer 2016; 15(1): 1-6.

[15] Cidon EU, Alonso P, Masters B, et al. Markers of response to antiangiogenic therapies in colorectal cancer: Where are we now and what should be next? Clin Med Insights Oncol 2016; 10(Suppl 1): 41-55.

[16] Varul U, Yidiz I, Saliman T, et al. Markers to predict the efficacy of bevacizumab in the treatment of metastatic colorectal cancer. Tumori 2014; 100: 370-76.

[17] Gonzalez-Vacarezza N, Alonso I, Gustavo JM, et al. Predictive biomarkers candidates for patients with metastatic colorectal cancer treat with bevacizumab-containing regimen. Drug Metabol Pers Ther 2016; 31(2): 83-90.

[18] Mir O, Coriat R, Cabanes L, et al. An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity. Oncologist 2011; 16(9): 1325-32.

[19] Mir O, Coriat R, Ropert S, et al. Treatment of bevacizumab-induced hypertension by amlopidine. Invest New Drugs 2012; 30(2): 702-7.

[20] Osterlund P, Soveri LM, Isoniemi H, et al. Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Br J Cancer 2011; 104: 599-604.

[21] Lee JC, Chow NH, Wang ST, et al. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 2000; 36: 748-53.

[22] Osterlund P, Soveri LM, Isoniemi H, et al. Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Br J Cancer 2011; 104: 599-604.

[23] Zhou J, Zhang H, Wang H, et al. Early prediction of tumor response to bevacizumab treatment in murine colon cancer models using three-dimensional dynamic contrast-enhanced ultrasound imaging. Angiogenesis doi: 10.1007/s10456-017-9566-5.

[24] Hirashima Y, Yamada Y, Tateishi U, et al. Pharmacokinetic parameters from 3-tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis. Int J Cancer 2012; 130: 2359-65.

[25] Lee L, Sharma S, Morgan B, et al. Biomarkers for assessment of pharmaco-logic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases. Cancer Chemother Pharmacol 2006; 57(6): 761-71.

[26] Troprès I, Lamalle L, Péoc’h M, et al. Assessment of tumoral angiogenesis. Magn Reson Med 2004; 51: 533-41.

[27] Zwick S, Strecker R, Kiselev V, et al. Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging. J Magn Reson Imaging 2009; 29: 1125-33.

[28] Walker-Samuel S, Boulh JK, et al. Non-invasive in vivo imaging of vessel calibre in orthotopic prostate tumour xenografts. Int J Cancer 2012; 130: 1284-93.

[29] Gilad AA, Israel T, Dafni H, et al. Functional and molecular mapping of uncoupling between vascular permeability and loss of vascular maturation in ovarian carcinoma xenografts: The role of stroma cells in tumor angiogenesis. Int J Cancer 2005; 117: 202-11.
Dynamic Biomarkers to Antiangiogenic Therapies in CRC  
Current Pharmacogenomics and Personalized Medicine, 2017, Vol. 15, No. 2  
85

[27] Manning HC, Merchant NB, Foutch AC, et al. Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer. Clin Cancer Res 2008; 14: 7413-22.

[28] Maitland ML, Kasza KE, Karrison T, et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res 2009; 15(19): 6250-7.

[29] Mass RD, Sarkar S, Holden SN, et al. Clinical bene t from bevacizumab in responding and nonresponding patients with metastatic colorectal cancer. J Clin Oncol 2005; 23: S249.

[30] Poon RT, Fan ST, Wong J, et al. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001; 19: 1207-25.

[31] Jubb AM, Hurwitz HI, Bai W, et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006; 24: 217-27.

[32] Willett CG, Duda DG, di Tomaso E, et al. Efficacy, safety and biomarkers of neoadjuvant bevacizumab, radiation therapy and 5-Fluorouracil in rectal cancer: A multidisciplinary phase II study. J Clin Oncol 2009; 27(18): 3020-6.

[33] George DJ, Michaelson MD, Rosenberg JE, et al. Phase II trial of sunitinib in bevacizumab refractory metastatic renal cell carcinoma (mRCC): Updated results and analysis of circulating biomarkers [abstract #5053]. J Clin Oncol 2007; 25(suppl): S18.

[34] Dowlati A, Gray R, Sandler AB, et al. Cell adhesion molecules, vascular endothelial growth factor, and basic broblast factor growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab an Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008; 14: 1407-12.

[35] Depriamo SE, Bello CL, Smeraglia J, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: Modulation of VEGF and VEGF-related proteins. J Transl Med 2007; 5: 32.

[36] Schneider BP, Wang M, Radovich M, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008; 26: 4672-8.

[37] Zhu AX, Sahani DV, Duda DG, et al. Efficacy, safety and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study. J Clin Oncol 2009; 27(18): 3027-35.

[38] Fischer C, Jonckx B, Mazzone M, et al. Anti-PIGF inhibits growth of VEGF(R) inhibitor-resistant tumors without a ecting healthy vessels. Cell 2007; 131: 463-75.

[39] Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with Bevacizumab refractory metastatic renal cell carcinoma. J Clin Oncol 2008; 26: 3743-8.

[40] Loaiza-Bonilla A, Jensen CE, Shroff S, et al. KDR Muta- tion as a novel predictive biomarker of exceptional response to Regorafenib in metastatic colorectal cancer. Cureus 2016; 8(2): e48.

[41] Kim S, Cayre A, Jury M, et al. Complete response to aflibercept-FOLFIRI in one patient with colorectal cancer refractory to Bevacizumab-FOLFIRI: A possible autocrine vascular endothelial growth factor receptor 2-related mechanism. Clin Colorectal Cancer 2016; doi: 10.1016/j.clcc.2016.07.015.

[42] Willett CG, Boucher Y, Duda DG, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for Bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005; 23: 8136-9.

[43] Dowlati A, Gray R, Sandler AB, Schiller JH, Johnson DH. Cell adhesion molecules, vascular endothelial growth factor, and basic broblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab an Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008; 14: 1407-12.

[44] Zuurbier L, Rahman A, Cordes M, et al. Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer. Oncotarget 2017; 8(26): 42949-61.

[45] Kopetz S, Hoff PM, Morris JS, et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: Efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. Clin Oncol 2010; 28: 453-9.

[46] Antonio CA; Alvarez-Gallego R; Munoz M, et al. Dynamic angiogenic switch as predictor of response to chemotherapy+ Bevacizumab in patients with metastatic colorectal cancer. J Clin Oncol 2016; 10.1200/JCO.2016.34.15._ suppl.e15126.

[47] Bunner S, Haug U, Kelly FM, et al. Toward standardized high-throughput serum diagnostics: Multiplex-protein array identi es IL-8 and VEGF as serum markers for colon cancer. J Biomol Screen 2011; 16: 1018-26.

[48] Li A, Dubey S, Varney ML, Dave BJ, Singh RK. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003; 170: 3369-76.

[49] Hayashi H, Tokuzo A, Kazuko M, et al. Biomarkers of reactive resistance and early disease progression during chemotherapy plus Bevacizumab treatment for colorectal carcinoma. Oncotarget 2014; 5(9): 2588-95.

[50] Simicrome FA, Sargent DJ. Clinical implications of microsatellite instability in sporadic colon cancers. Curr Opin Oncol 2009; 4: 369-73.

[51] Giordano G, Febbraro A, Venditti M, et al. Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: Role of aflibercept. Gastroenterol Res Pract 2014; 2014: 526178.

[52] Ma J, Zhao J, Lu J, et al. Cadherin-12 enhances proliferation in colorectal cancer cells and increases progression by promoting EMT. Tumour Biol 2016; 37(7): 9077-88.

[53] Zhang J, Zhu L, Fang J, et al. LRG1 modulates epithelial-mesenchymal transition and angiogenesis in colorectal cancer via HIF-1a activation. J Exp Clin Cancer Res 2016; 35: 29.